New drug combo for aggressive B-cell lymphoma that hasn't been treated yet
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a combination of four drugs (G-Pola-GemOx) for people with aggressive B-cell lymphoma who have not had chemotherapy before. The goal is to see if this new treatment can help control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of aggressive B-cell lymphoma, like diffuse large B-cell lymphoma or mantle cell lymphoma.
- You must be 18 years or older.
- You must not have received any chemotherapy for your lymphoma in the past.
- You must be expected to live at least 3 more months.
- You must not have any serious, uncontrolled infections or other major health problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (glofitamab plus gemcitabine and oxaliplatin) for people with aggressive B-cell lymphoma that has returned or not responded to prior treatment. The goal is to see if this approach can improve outcomes while managing side effects.
This trial tests a combination of three targeted drugs (glofitamab, polatuzumab vedotin, and zuberitamab) for people with newly diagnosed, aggressive B-cell lymphoma that hasn't been treated yet. The goal is to see if this combination works better than standard therapy.
This trial tests a combination of three drugs (G-Pola-ZLP) for people with newly diagnosed Diffuse Large B-Cell Lymphoma who have not had chemotherapy before. The goal is to see if this treatment works well and is safe.
This trial tests a new drug called glofitamab, combined with standard chemotherapy, for people whose large B-cell lymphoma came back or didn't respond to their first treatment. It aims to see if this combination works better than the usual approach.
This trial tests a combination of three targeted drugs (tafasitamab, polatuzumab vedotin, and glofitamab) as a first treatment for diffuse large B-cell lymphoma or high-grade B-cell lymphoma. It aims to see if this approach can be effective without standard chemotherapy.
This trial tests a combination of medicines (Pola-R-CHP plus a new drug called Sonrotoclax) for newly diagnosed aggressive B-cell lymphoma, especially cases with high BCL-2 protein or double-hit features. The goal is to see if adding Sonrotoclax helps control the cancer better.
Hear when a new Aggressive B-Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.